Trial designs and endpoints for immune therapies in multiple myeloma

被引：3

作者：

Lancman, Guido ^{[1
]}

Moshier, Erin ^{[2
]}

Cho, Hearn Jay ^{[1
]}

Parekh, Samir ^{[1
]}

Richard, Shambavi ^{[1
]}

Richter, Joshua ^{[1
]}

Rodriguez, Cesar ^{[1
]}

Rossi, Adriana ^{[1
]}

Sanchez, Larysa ^{[1
]}

Jagannath, Sundar ^{[1
]}

Chari, Ajai ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Hematol & Med Oncol, 1 Gustave L Levy Pl,Box 1185, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷

关键词：

T-CELL THERAPY; BELANTAMAB MAFODOTIN; DEXAMETHASONE; EXPANSION; EFFICACY; DREAMM-2; OUTCOMES; CARE; BCMA;

D O I：

10.1002/ajh.26753

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune therapies, including CAR-T cells, bispecific antibodies, and antibody-drug conjugates, are revolutionizing the treatment of multiple myeloma. In this review, we discuss clinical trial design considerations relevant to immune therapies. We first examine issues pertinent to specific populations, including elderly, patients with renal impairment, high-risk/extramedullary disease, and prior immune therapies. We then highlight trial designs to optimize the selection of dose and schedule, explore rational combination therapies based on preclinical data, and evaluate the nuances of commonly used endpoints. By exploiting their pharmacokinetic/pharmacodynamic profiles and utilizing novel translational insights, we can optimize the use of immune therapies in multiple myeloma.

引用

页码：S35 / S45

页数：11

共 50 条

[1] Immune Therapies in Multiple Myeloma
Kumar, Shaji K.
Anderson, Kenneth C.
CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5453 - 5460
[2] Immune therapies in the treatment of multiple myeloma
Brugnara, Carlo
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S3 - S3
[3] Promise of Immune Therapies in Multiple Myeloma
Anderson, Kenneth C.
JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (07) : 411 - +
[4] Clinical trial designs for multiple myeloma
Hoering, A.
Crowley, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 207 - 207
[5] Integrating Immune Therapies for the Treatment of Multiple Myeloma
Mikkilineni, Lekha
Sidana, Surbhi
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (12): : 1303 - 1311
[6] Clinical Trial Designs for New Therapies: What Endpoints Should We Use?
Hudis, C. A.
CANCER RESEARCH, 2012, 72
[7] Immune-based therapies in the management of multiple myeloma
Zanwar, Saurabh
Nandakumar, Bharat
Kumar, Shaji
BLOOD CANCER JOURNAL, 2020, 10 (08)
[8] Immune-based therapies in the management of multiple myeloma
Saurabh Zanwar
Bharat Nandakumar
Shaji Kumar
Blood Cancer Journal, 10
[9] Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies
Kumar, Shaji
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 518 - 524
[10] The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt
Mohyuddin, Ghulam Rehman
Ouchveridze, Evguenia
Goodman, Aaron
Prasad, Vinay
LEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2793 - 2795

← 1 2 3 4 5 →